MedWatch

Analysts predict possible 2021 guidance upgrade from Demant

Several analysts foresee hearing aid company Demant upgrading guidance for its organic growth or operating result in the coming quarterly report. This might already be reflected in the share price, however.

Photo: Demant / PR

Hearing aid manufacturer Demant may be forthcoming with an upgrade on organic growth or earnings before interest and taxes when the company presents its second-quarter financial statement on Thursday, Aug. 12.

Furthermore, ABG Sundal Collier raise its target price for Demant stock, according to Bloomberg News and PLX.AI.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs